-
3 days ago | 
contagionlive.com | John Parkinson |Paul A. Offit
The Johns Hopkins Bloomberg School of Public Health’s Center for Outbreak Response Innovation has a measles outbreak tracker.
-
6 days ago | 
contagionlive.com | John Parkinson |Anu Osinusi
In a late-breaking oral presentation at EASL, 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) who were treated with the first-in-class entry inhibitor bulevirtide, at either a 2 mg or 10 mg dose, maintained virologic suppression for nearly 2 years after treatment, following undetectable HDV RNA when they finished their treatment. These findings were part of Gilead’s phase 3 MYR301 trial.
-
1 week ago | 
contagionlive.com | John Parkinson |Anu Osinusi
At the ongoing European Association for the Study of the Liver (EASL) Congress 2025, Gilead announced findings on its hepatitis D (HDV) therapy, bulevirtide. Specifically, the therapy was studied as a standalone treatment and in combination with pegylated interferon alpha (PegIFN).
-
1 week ago | 
contagionlive.com | John Parkinson
At the ongoing European Association for the Study of the Liver (EASL) Congress 2025, Atea Pharmaceuticals announced the full results from its phase 2 clinical trial, which showed a 98% sustained virologic response rate at 12 weeks post-treatment (SVR12) in 210 of 215 participants with the regimen in the “Per-Protocol Treatment-Adherent Population,” using an 8-week treatment duration.
-
1 week ago | 
contagionlive.com | John Parkinson |Paul A. Offit
Health and Human Services Secretary Robert F Kennedy Jr is reported to have asked the Centers for Disease Control and Prevention (CDC) to develop new guidance for treating measles with therapies and vitamins.
-
1 week ago | 
contagionlive.com | John Parkinson
The PROVE (Retrospective Cefiderocol Chart Review) study is a 5-year international, retrospective, observational medical chart review study, conducted between November 2020 and July 2024 designed to describe the efficacy and safety of real-world cefiderocol use in adult patients with serious gram-negative (GN) bacterial infections. This aforementioned data comes from the European cohort.1The results from the trial are still being analyzed and reported.
-
1 week ago | 
contagionlive.com | John Parkinson
On World Hand Hygiene Day, The National Foundation for Infectious Diseases released its 2025 State of Handwashing Report, based on a new national survey of US adult handwashing knowledge and behaviors. The survey showed that 48% of US adults admit to forgetting or choosing not to wash their hands at key times, like after visiting grocery stores, restaurants or coffee shops, or a healthcare setting (doctor’s office, pharmacy, clinic, or hospital).
-
2 weeks ago | 
contagionlive.com | John Parkinson
The FDA has requested that Moderna provide more data for its late-stage mRNA-1083 combination influenza/COVID-19 vaccine.
-
2 weeks ago | 
contagionlive.com | John Parkinson
Today, the Leapfrog Group released its Spring 2025 Hospital Safety Grades assigning letter grades to each state. States with the highest percentage of A grades for this cycle are Utah, Rhode Island, New Jersey, Connecticut, South Carolina and Virginia.1 Utah ranked number 1 for the fourth consecutive safety grade round, and ties for first among states with the highest percentage of Straight A hospitals.
-
2 weeks ago | 
contagionlive.com | John Parkinson
During a hepatitis E outbreak in 2022 in South Sudan at the Bentiu refugee camp, the Hecolin HEV vaccine was shown to be highly protective. The results were published in The Lancet Infectious Diseases. “In the primary analysis we estimated an unadjusted two-dose vaccine effectiveness of 67.8% (95% CI –28.6 to 91.9), and a 2-dose vaccine effectiveness of 84.0% (–2085 to 992) after adjustment for potential confounders,” the investigators wrote.
